GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellular Biomedicine Group Inc (NAS:CBMG) » Definitions » ROC (Joel Greenblatt) %

Cellular Biomedicine Group (Cellular Biomedicine Group) ROC (Joel Greenblatt) % : -167.80% (As of Sep. 2020)


View and export this data going back to 2007. Start your Free Trial

What is Cellular Biomedicine Group ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Cellular Biomedicine Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2020 was -167.80%.

The historical rank and industry rank for Cellular Biomedicine Group's ROC (Joel Greenblatt) % or its related term are showing as below:

CBMG's ROC (Joel Greenblatt) % is not ranked *
in the Biotechnology industry.
Industry Median: -334.375
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

Cellular Biomedicine Group's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Cellular Biomedicine Group ROC (Joel Greenblatt) % Historical Data

The historical data trend for Cellular Biomedicine Group's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellular Biomedicine Group ROC (Joel Greenblatt) % Chart

Cellular Biomedicine Group Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,023.76 -691.27 -322.71 -170.46 -125.64

Cellular Biomedicine Group Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -150.17 -112.44 -98.76 -130.84 -167.80

Competitive Comparison of Cellular Biomedicine Group's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Cellular Biomedicine Group's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellular Biomedicine Group's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellular Biomedicine Group's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Cellular Biomedicine Group's ROC (Joel Greenblatt) % falls into.



Cellular Biomedicine Group ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2020 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.094) - (3.255 + 0 + 5.722)
=-7.883

Working Capital(Q: Sep. 2020 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.032 + 0 + 1.512) - (4.504 + 0 + 6.923)
=-9.883

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Cellular Biomedicine Group for the quarter that ended in Sep. 2020 can be restated as:

ROC (Joel Greenblatt) %(Q: Sep. 2020 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2020  Q: Sep. 2020
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-70.748/( ( (41.114 + max(-7.883, 0)) + (43.208 + max(-9.883, 0)) )/ 2 )
=-70.748/( ( 41.114 + 43.208 )/ 2 )
=-70.748/42.161
=-167.80 %

Note: The EBIT data used here is four times the quarterly (Sep. 2020) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cellular Biomedicine Group  (NAS:CBMG) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Cellular Biomedicine Group ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Cellular Biomedicine Group's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellular Biomedicine Group (Cellular Biomedicine Group) Business Description

Traded in Other Exchanges
N/A
Address
1345 Avenue of Americas, 15th Floor, New York, NY, USA, 10105
Cellular Biomedicine Group Inc is a biotechnology company focused on the development of proprietary cell therapies for the treatment of cancer and degenerative diseases. The company has two major cell platforms: immune cell therapy for treating a broad range of cancers using cancer vaccines, Chimeric Antigen Receptor T-cell technologies, and anti-PD-1 technologies; and human-adipose-derived mesenchymal progenitor cells for treatment of joint and autoimmune diseases. The immuno-oncology and stem cell research team is based in both China and the United States.
Executives
Ag Novartis 10 percent owner LICHTSTRASSE 35, BASEL V8 CH 4056
Pharma Ag Novartis 10 percent owner LICHTSTRASSE 35, CH-4002, BASEL V8
Edward T Schafer director 1400 31ST AVENUE SW, SUITE 60, MINOT ND 58701
Wen Tao Liu director 530 UNIVERSITY AVENUE, #17 PALO ALTO CA 94301
Terry Belmont director 530 UNIVERSITY DRIVE PALO ALTO CA 94301
Au Chun Kwok Alan director C/O CELLULAR BIOMEDICINE GROUP, INC. 530 UNIVERSITY AVENUE, #17 NEW YORK NY 94301
Hansheng Zhou director 369 LUMO ROAD HONGSHAN DISTRICT WUHAN F4 430074
Gang Jacky Ji director XIXI RONGZHUANG 27-3 JINGCHANG ROAD, YUHANG DISTRICT, HANGZHOU, ZHEJIANG F4 311100
Viktor Pan 10 percent owner HELI XI LU 183 NO. 531 SHANGHAI F4 201317
Srl Opea director VIA CESARE BATTISTA 1 MILAN L6 20122
Zheng Zhou 10 percent owner FLAT B, 25/F, TOWER 6, MARINELLA 9 WELFARE ROAD, ABERDEEN HONG KONG K3 00000
Sailing Capital Overseas Investments Fund, Lp 10 percent owner C/O UNIT 2006-08, 20F HARBOUR CENTRE 25 HARBOUR ROAD WAN CHAI K3 00000
Maplebrook Ltd 10 percent owner P.O. BOX 31119 GRAND PAVILLION HIBISCUS WAY, 802 WEST BAY ROAD GRAND CAYMAN E9 KY1-1205
Tf Venture Capital Management Co., Ltd. 10 percent owner PO BOX 472, 2ND FLOOR, HARBOUR PLACE 103 SOUTH CHURCH STREET, GEORGE TOWN GRAND CAYMAN E9 KY1-1106
Winsor Capital Ltd 10 percent owner TRINITY CHAMBERS PO BOX 4301, ROAD TOWN TORTOLA D8 00000

Cellular Biomedicine Group (Cellular Biomedicine Group) Headlines

From GuruFocus

Cellular Biomedicine Group, Inc. Announces Completion of Merger

By PRNewswire PRNewswire 02-19-2021